- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off ; volume:20 ; number:1 ; day:12 ; month:10 ; year:2021 ; pages:1-5 ; date:12.2021
Cardiovascular diabetology ; 20, Heft 1 (12.10.2021), 1-5, 12.2021
- Creator
-
Giugliano, Dario
Scappaticcio, Lorenzo
Longo, Miriam
Bellastella, Giuseppe
Esposito, Katherine
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-021-01400-9
- URN
-
urn:nbn:de:101:1-2021122621291441929096
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Giugliano, Dario
- Scappaticcio, Lorenzo
- Longo, Miriam
- Bellastella, Giuseppe
- Esposito, Katherine
- SpringerLink (Online service)
Other Objects (12)
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Nothing Seems Legit NSL
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β ‐Klotho‐Mediated Ferroptosis Inhibition
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Nothing Seems Legit NSL
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β ‐Klotho‐Mediated Ferroptosis Inhibition
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Nothing Seems Legit NSL
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?